Swiss biotech Noema has added another $112 million to its funding in an oversubscribed second round, as it takes neurological disorder drugs licensed in from Roche through clinical development.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,